Phoenix A. Ho - Concepedia

Author

Phoenix A. Ho

Fred Hutch Cancer Center ORCID

Also Known As

P A Ho, Phoenix A. Ho, Phoenix Ho

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Fred Hutch Cancer Center University of Southern California St. Jude Children's Research Hospital Children's Oncology Group University of Washington

About

Phoenix A. Ho is an author at Fred Hutch Cancer Center specializing in cancer research, molecular oncology, and cancer biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	96
2	Pathology	1	1	96
3	Cancer Genetics	1	1	96
4	Molecular Oncology	1	1	96
5	Cancer Biology	1	1	96

Phoenix A. Ho

Publications

Citations

H-Index

Page 1

	Year	Citations
Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group Michael R. Loken, Todd A. Alonzo, Laura Pardo, Blood	2012	291
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group Phoenix A. Ho, Todd A. Alonzo, Robert B. Gerbing, Blood	2009	216
Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML Jessica A. Pollard, Todd A. Alonzo, Robert B. Gerbing, Blood	2010	181
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia Eytan M. Stein, Roland B. Walter, Harry P. Erba, Blood	2017	177
Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients Sioḃán Keel, Angela Scott, Marilyn Sánchez-Bonilla, Haematologica	2016	152
C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations John Anto Pulikkan, Philomina Sona Peramangalam, Viola Dengler, Blood	2010	124
Leukemic mutations in the methylation‐associated genes <i>DNMT3A</i> and <i>IDH2</i> are rare events in pediatric AML: A report from the Children's Oncology Group Phoenix A. Ho, Matthew A. Kutny, Todd A. Alonzo, Pediatric Blood & Cancer	2011	122
Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML Jessica A. Pollard, Todd A. Alonzo, Michael R. Loken, Blood	2012	110
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML Amir T. Fathi, Harry P. Erba, Jeffrey E. Lancet, Blood	2018	102
Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study Phoenix A. Ho, Todd A. Alonzo, Kenneth J. Kopecky, Leukemia Oncology GroupOncologySomatic VariantMedicineIdh1 Gene	2010	96

Page 1